Patent ID: 7262018
Filing Date: 2007-08-28
Classification: G01N,Y10T

Abstract:
1. A method of determining whether cytochrome P450 2C19 metabolizes a compound, comprising: contacting the compound with cytochrome P450 2C19 in the presence of varying amounts of a binding agent; and assaying metabolism of the compound as a function of amount of binding agent, a decrease of metabolism of the compound corresponding with an increase of amount of binding agent indicating that cytochrome P450 2C19 metabolizes the compound; wherein the binding agent comprises an isolated antibody or fragment thereof that competes with a monoclonal antibody selected from the group consisting of MAb 1-7-4-8 (ATCC PTA-3970), MAb 1-5-1-3 (ATCC PTA-3969), and MAb 1-1-11-1 (ATCC PTA-3971) for specific binding to human cytochrome P450 2C19, and that specifically inhibits 2C19-catalyzed metabolism of diazepam and phenanthrene by at least 85%.